mechanism of action of glp 1 receptor agonists Frontiers GLP-1 Agonists For Obesity In
Description
This was despite the fact that the work behind the patent, filed in 1997 and granted in 2001, demonstrated that the peptide helped to lower body weight for four weeks in type 2 diabetes patients who were obese (DiMarchi, Efendic)

Potential role of glucagon-like peptide-1 (GLP-1) receptor agonists in substance use disorder: a systematic review of randomized trials

The primary one is competition from other GLP-1 drugs, especially from Eli Lillys Mounjaro (tirzepatide), which has shown greater efficacy in weight loss and diabetes control

doi: 10.2337/dc10-1949

Study limitations This meta-analysis has several limitations that should be considered when interpreting the findings

Their role in the pathophysiology of type 2 diabetes (T2D) has been well-characterized, and augmentation by incretin-based therapies leads to improved glycemic control 6
